{
    "clinical_study": {
        "@rank": "112765", 
        "arm_group": [
            {
                "arm_group_label": "SOBI002", 
                "arm_group_type": "Experimental", 
                "description": "Single and repeated administration of different doses of test product"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Experimental", 
                "description": "Matching reference product"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to assess the safety and tolerability of SOBI002 in\n      healthy volunteers following single and repeated administration."
        }, 
        "brief_title": "Safety and Tolerability of SOBI002 in Healthy Volunteers Following Single and Repeated Administration", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This is a double-blind, placebo-controlled, randomized within dose cohort single and\n      repeated dose study with sequential dose escalation.\n\n      Eligible volunteers will be divided into dose cohorts and for each cohort, a new panel of 8\n      volunteers will be randomized to receive either SOBI002 (n=6) or placebo (n=2). SOBI002 will\n      either be administered subcutaneously or intravenously."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Females of non-childbearing potential or males\n\n          -  18 to 45 years of age\n\n          -  Judged by the Principal Investigator to be healthy on the basis of medical history\n             and a pre-study physical examination including 12-lead electrocardiogram (ECG),\n             24-hour Holter ECG, vital signs and blood and urine laboratory assessments.\n\n        Exclusion Criteria:\n\n          -  Females of childbearing potential\n\n          -  Clinically significant disease\n\n          -  Clinically significant abnormal laboratory, ECG, vital signs or other safety findings\n             as determined by medical history, physical examination or other evaluations conducted\n             at screening or on admission."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02083666", 
            "org_study_id": "SOBI002-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "SOBI002", 
                "description": "Test Product", 
                "intervention_name": "SOBI002", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "Reference product", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase I", 
            "Dose cohorts", 
            "Escalating dose", 
            "Single dose", 
            "Multiple dose", 
            "Safety", 
            "Tolerability", 
            "Pharmacokinetics", 
            "Pharmacodynamics", 
            "volunteers"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": {
            "contact": {
                "email": "u.lorch@richmondpharmacology.com", 
                "last_name": "Ulrike Lorche, MD FRCA FFPM", 
                "phone": "+442086645200"
            }, 
            "contact_backup": {
                "email": "l.schram@richmondpharmacology.com", 
                "last_name": "Linh Schram", 
                "phone": "+442086645200"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "state": "St George's University of London", 
                    "zip": "SW17 0RE"
                }, 
                "name": "Richmond Pharmacology Ltd."
            }, 
            "investigator": {
                "last_name": "Ulrike Lorch, MD FRCA FFPM", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SOBI002 Following Subcutaneous and Intravenous Administration. A Double-blind, Placebo-controlled, Randomized Within Dose Cohort, Single and Repeated Dose-escalation Study in Healthy Volunteers", 
        "overall_contact": {
            "email": "karin.grunbaum@sobi.com", 
            "last_name": "Karin Gr\u00fcnbaum, MSc Pharm", 
            "phone": "+46760011502"
        }, 
        "overall_contact_backup": {
            "email": "elin.rosendahl@sobi.com", 
            "last_name": "Elin Rosendahl, MSc Pharm", 
            "phone": "+4686973142"
        }, 
        "overall_official": {
            "affiliation": "Swedish Orphan Biovitrum AB (publ)", 
            "last_name": "Hans Olivecrona, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety will be evaluated by assessing all Adverse Events, vital signs, 12-lead ECGs, urine samples for determination of urinalysis variables and blood samples for determination of hematology, biochemistry and coagulation variables.", 
            "measure": "To assess the safety and tolerability of SOBI002 in healthy volunteers following single and repeated adminstration", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 13 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02083666"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assessment of pharmacokinetics of SOBI002 through analysis of serum samples", 
                "safety_issue": "No", 
                "time_frame": "Up to 13 weeks"
            }, 
            {
                "measure": "Assessment of pharmacodynamics by assessing the inhibition of SOBI002 on hemolytic activity", 
                "safety_issue": "No", 
                "time_frame": "Up to 13 weeks"
            }, 
            {
                "measure": "Assessment of the immungenicity of SOBI002 by measuring the occurence of anti-drug antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 13 weeks"
            }
        ], 
        "source": "Swedish Orphan Biovitrum", 
        "sponsors": {
            "collaborator": {
                "agency": "Richmond Pharmaceuticals Ltd.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Swedish Orphan Biovitrum", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}